Follicular Lymphoma >  ASCO 2012 - MCL abstracts

Last update: 05/30/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

1. Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL). | 2012 ASCO Annual Meeting Abstracts
    

2. Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models. | 2012 ASCO Annual Meeting Abstracts
    

3. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. | 2012 ASCO Annual Meeting Abstracts
    

4. A retrospective study analyzing activity of ofatumumab in blastic variant mantle cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
    

5. Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors. | 2012 ASCO Annual Meeting Abstracts
    

6. Improving outcomes in mantle cell lymphoma patients treated with R-CHOP using autologous transplant. | 2012 ASCO Annual Meeting Abstracts
    

7. A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). | 2012 ASCO Annual Meeting Abstracts
    

8. Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX.

9. Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL).

10. Pharmacokinetics (PK) of bendamustine when administered in combination with rituximab in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).

11. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. | 2012 ASCO Annual Meeting Abstracts
     

12. Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma. | 2012 ASCO Annual Meeting Abstracts
     

13. Expression of mTOR in diffuse large B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
     

14. Impact of lower chemotherapy dose on treatment outcome and survival of patients with advanced Hodgkin lymphoma: Single institution experience. | 2012 ASCO Annual Meeting Abstracts
     

15. Natural history and clinical prognosis of in situ mantle cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
     

16. Unusual primary presentations of mantle cell lymphoma in the urinary tract and testes. | 2012 ASCO Annual Meeting Abstracts